Heron Therapeutics reported a GAAP loss of $63.888 million for the first 3 months of 2022, up 21.4% from $52.614 million in the prior year. Revenue increased 17.2% to $23.457 million from $20.018 million a year earlier.
Heron Therapeutics reported a GAAP loss of $63.888 million for the first 3 months of 2022, up 21.4% from $52.614 million in the prior year. Revenue increased 17.2% to $23.457 million from $20.018 million a year earlier. 
ir.herontx.com
English (US) 